Fintech PR
Tigermed Reports 2023 Interim Results
HANGZHOU, China, Aug. 25, 2023 /PRNewswire/ — Hangzhou Tigermed Consulting Co., Ltd. (“Tigermed” or the “company”) (Stock code: 300347.SZ / 3347.HK), a leading provider of clinical research solutions across full lifecycle of global biopharmaceutical and medical device products, announced its interim results for the first half of 2023, ended June 30, 2023 (the “Reporting Period”).
|
This press release is for information and summary only and is not intended to provide any representation, in whole or in part, of the relevant matters. For further information, please refer to the 2023 interim results and relevant announcements published on the websites of the Shenzhen Stock Exchange (www.szse.cn) and the Stock Exchange of Hong Kong (www.hkexnews.hk). |
|
All financials disclosed in this press release are prepared based on International Financial Reporting Standards (IFRS) except for those specifically noted otherwise. The 2023 Interim Results of the company has not been audited. |
First Half 2023 Financial Performance
- Total revenue achieved 3.2% year-over-year (“YoY”) growth to RMB 3,710.9 million during the Reporting Period.
- Adjusted Net Profit Attributable to the Owners of the Company(1) increased by 2.2 % YoY to RMB 895.6 million during the Reporting Period（1）.
- Segment revenue generated from Clinical Trial Solutions decreased by 3.2% YoY to RMB 2,103.4 million.
- Segment revenue generated from Clinical-related and Lab Services achieved 13% YoY growth and reached RMB 1,607.5 million.
- Geographically, China’s revenue increased by 24.2% YoY to RMB 2,087.4 million. The company’s overseas revenue decreased by 15.2% YoY to RMB 1,623.5 million during the Reporting Period.
|
（1）Non-IFRS measure. Adjusted for (i) share-based compensation expense, (ii) net foreign exchange loss/(gain), (iii) amortization of intangible assets arising from acquisitions, and (iv) changes in fair value of financial assets at FVTPL |
Business Highlight:
Tigermed maintained its strong position in the CRO industry in the first half of 2023 by providing comprehensive services and empowering global biopharmaceutical innovation with high quality and commitment. As of June 30, 2023, Tigermed had 772 ongoing drug clinical research projects, including over 40 ongoing clinical trials in the United States, 35 ongoing clinical trial projects in the EMEA (Europe, Middle East, Africa) region, and 31 ongoing clinical trial projects in South East Asia and Latin America regions.
During the reporting period, Tigermed regulatory affairs (RA) business had 940 accumulated project experience, added 18 new U.S. FDA IND projects, and assisted 7 products to be registered and approved in China. Furthermore, the Tigermed medical device team has served over 1,700 global clients with 5,700+ accumulated medical device and IVD registration projects, as well as 700+ clinical trial experiences.
Tigermed has achieved impressive growth in pharmacovigilance, medical translation, and real-world studies services in the first half of 2023. Notably, pharmacovigilance services added 75 newly signed projects and 59 new customers, providing safety monitoring solutions to both pre-NDA and post-market projects in both Europe and China. Medical translation added 52 new customers while expanding into the Japanese market in 2023. Real-World Study (RWS) business has reached multiple collaborations with global pharmaceutical companies. In terms of vaccine clinical service, Tigermed team has conducted 14 overseas COVID-19 vaccine projects and supported multiple innovative vaccines to carry out phase III protective efficacy research.
As of June 30, 2023, data management and statistical analysis had 296 customers and 859 ongoing projects. Additionally, Tigermed had 1,776 ongoing site management projects and provided services for 11 Class I innovative drug approvals in China in the first half of 2023. Furthermore, Tigermed Excellence for Clinical Trial Sites (“E-Site”) Program had 204 core collaborative sites and 61 green channel sites across China, forming a diversified and win-win strategic cooperation model.
Tigermed laboratory service has achieved great progress as of June 30, 2023. The Frontage Suzhou Safety Assessment Center obtained the GLP (Good Laboratory Practice) certification issued by the NMPA; the new 8,000+ square meters clinical trial manufacture center in Suzhou was officially put into operation; and ACME Biopharma, a subsidiary of Frontage, launched its Wuhan R&D center, offering comprehensive R&D services from target screening to pre-clinical pharmacology research.
During the reporting period, Tigermed DCTs (Decentralized Clinical Trials) Solutions were put into use across several therapeutic areas, such as oncology, Alzheimer’s disease, migraine, diabetes, COVID-19, etc., creating functions including remote follow-up, remote monitoring, remote informing, electronic patient report, etc. Furthermore, the company compiled The Tigermed DCT Global Regulatory Handbook, which became a regulatory reference and guide for DCT applications in global clinical research.
In the first half of 2023, Tigermed achieved a major milestone in its globalization efforts by establishing its International Headquarters in Hong Kong, which will enable the company to coordinate and manage global projects more efficiently and empower customers on a global scale.
As of June 30, 2023, Tigermed total number of employees reached 9,455, of which 1,525 were based overseas. During the reporting period, Tigermed had cumulative experience handling 120+ MRCT projects and 62 ongoing MRCTs. In addition, Tigermed acquired Marti Farm to further strengthen its ability to provide high-quality clinical services in Europe for global customers.
Tigermed has earned recognition from customers, industry, and media across the globe. During the reporting period, Tigermed has been honored with awards such as “Microsoft Digital Platform Best Practices Awards”, “Best Employer Brand on LinkedIn”, and “Best Medical Device Overseas Enabling Service Provider of 2023. Moreover, CSA Research ranked its medical translation business 51st globally (5th in mainland China and 14th in the Asia Pacific) according to the 2023 CSA Research Largest Language Service Providers Ranking.
Management Comment
“At Tigermed, we have taken the initiative to embrace the opportunities and challenges of the CRO industry in the first half of 2023,” said Ms. Xiaochun Cao, Co-Founder, Executive Director, and President of Tigermed. “We focus on globalization, digitalization, and integration as our driving strategies for corporate development, and our comprehensive and reliable clinical research services have helped us build our global reputation. We are consistently striving to enhance service capabilities and scaling our global reach while remaining committed to offering our clients a professional and reliable experience that will ultimately benefit healthcare worldwide.”
Forward-Looking Statements
The information communicated herein may contain certain “forward-looking statements”, which are not historical facts but instead include predictions about future events based on our beliefs and information currently made available to us. Although we believe that these predictions are reasonable on the date hereof, future events are inherently uncertain and these forward-looking statements may turn out to be incorrect. Forward-looking statements involve risk and uncertainty by nature because they relate to events and will depend on circumstances that will occur in the future relating to, inter alia, our ability to compete effectively, our ability to develop and market new service offerings, our ability to expand into new markets, the risks associated with listed subsidiaries of the Company, unforeseeable international tensions, regulatory or governmental scrutiny in certain countries, the impact of emergencies and other force majeure events. We undertake no obligations to update forward-looking statements or to adapt them to future events or developments except as required by applicable laws or listing rules. Any investment in any securities issued by the Company or its subsidiaries will also involve certain risks. There may be additional material risks that are currently not considered to be material or of which the Company and its advisors or representatives are unaware. Against the background of these uncertainties, you should not rely on these forward-looking statements.
Non-IFRS Measure
To supplement our financial information which are presented in accordance with IFRS, we use adjusted net profit attributable to owners of the Company as an additional financial measure, which is not required by, or presented in accordance with IFRS. We define adjusted net profit attributable to owners of the Company as profit for the year attributable to owners of the Company before certain expenses and amortization. We define adjusted net profit attributable to owners of the Company as profit attributable to owners of the Company adjusted for (1) share-based compensation expense, (2) net foreign exchange loss/(gain), (3) amortization of intangible assets arising from acquisitions, (4) listing expenses incurred by our Group, and (5) increase in fair value of financial assets at FVTPL. Adjusted net profit attributable to owners of the Company is not an alternative to (i) profit before tax, profit for the year or profit for the year attributable to owners of the Company (as determined in accordance with IFRS) as a measure of our operating performance, (ii) cash flows from operating, investing and financing activities as a measure of our ability to meet our cash needs, or (iii) any other measures of performance or liquidity. We believe that this non-IFRS measure is useful for understanding and assessing underlying business performance and operating trends, and that the owners of the company and we may benefit from referring to this non-IFRS measure in assessing our financial performance by eliminating the impact of certain unusual, non-recurring, non-cash and/or non-operating items that we do not consider indicative of the performance of our business. However, the presentation of this non-IFRS measure is not intended to, and should not, be considered in isolation from or as a substitute for the financial information prepared and presented in accordance with the IFRS. You should not view the non-IFRS measure on a stand-alone basis or as a substitute for results under the IFRS, or as being comparable to results or a similarly titled financial measure reported or forecasted by other companies.
About Tigermed
Tigermed (Stock code: 300347.SZ/3347.HK) is a leading global provider of integrated research and development solutions for biopharmaceutical and medical device industry. With a broad portfolio of services and a promise of quality, from preclinical development to clinical trial to commercialization, we are committed to moving our customers through their development journey efficiently and cost-effectively. Tigermed Group currently represents a worldwide network of more than 100 subsidiaries and 180 service locations, with over 10,000 employees Asia Pacific, Europe, North & South America and Africa. We are devoted to building an integrated platform that enables the boundless possibilities for the healthcare industry, embracing challenges to fulfill our commitment to serving unmet patients’ needs, and ultimately saving lives.
View original content:https://www.prnewswire.co.uk/news-releases/tigermed-reports-2023-interim-results-301910020.html
Fintech PR
Richardson Sales Performance Announces Acquisition of Challenger, Uniting Two Industry Leaders to Redefine the Future of Sales Training
PHILADELPHIA and CHICAGO, Sept. 16, 2024 /PRNewswire/ — Richardson Sales Performance (Richardson), a leading global provider of sales training solutions, today announced its acquisition of Challenger, world-renowned for their research-based Challenger selling approach. This strategic acquisition unites two of the most influential names in the sales performance industry, creating an unparalleled powerhouse poised to deliver innovative, high-impact solutions for sales organizations worldwide.
The combination of Richardson’s expertise in developing role-based sales capabilities and Challenger’s distinctive approach to challenging conventional thinking in sales, marketing, and customer service teams will equip both companies’ customers for greater success. Together, the two companies will offer a more comprehensive suite of solutions designed to elevate sales teams’ performance and drive measurable business outcomes.
Richardson and Challenger’s joint capabilities will provide customers with expanded access to best-in-class methodologies, cutting-edge technology, rich analytics, and a broader range of learning experiences. By leveraging the strengths of both organizations, customers will benefit from a more holistic approach to sales training, encompassing everything from consultative, agile selling skills to disruptive, insight-driven selling strategies.
“The combination of Richardson’s proven track record in equipping sellers with a wide range of sales capabilities and Challenger’s expertise in message creation and challenging conventional thinking creates a unique opportunity for our customers to develop sales teams that are both agile and differentiated,” said John Elsey, CEO of Richardson Sales Performance. “We are excited to join forces with Challenger to provide an unmatched range of solutions that will empower sales professionals to thrive in an increasingly competitive environment.”
The acquisition also opens up new opportunities for employees of both companies. Together, Richardson and Challenger will foster a collaborative and innovative environment where employees can access broader professional development opportunities, leverage combined resources, and contribute to shaping the future of sales training and performance improvement.
Andee Harris, CEO of Challenger, commented, “I believe that our employees are key to driving strategic success. By joining forces with Richardson, we are unlocking critical resources and capabilities that will enable us to accelerate our long-term objectives. This acquisition positions us to enhance both our competitive edge and the opportunities we can offer our team members, strengthening our ability to deliver exceptional value to our customers.”
This transaction has been supported by Richardson’s financial sponsor, Truelink, which was launched in 2022 by Todd Golditch and Luke Myers to work with companies in the industrials and tech-enabled services sectors. The firm’s senior team brings decades of experience to their portfolio company partners, an extensive history of creating value together, and well-established strategies to improve processes, fuel growth, and enhance earnings.
Houlihan Lokey served as the exclusive financial advisor to Challenger.
About Richardson Sales Performance
Richardson is how leading sales organizations around the world are getting better results from their investment in sales training. For far too long, companies have had to deal with a big disconnect between their training and their real results in the field. We connect metrics to behaviors, training to outcomes and sellers to their best performance. For more information, visit www.richardson.com
About Challenger
Challenger is the global leader in training, technology, and consulting to win today’s complex sale. The company delivers a comprehensive portfolio of solutions to sales, marketing and customer service teams. Challenger’s training and consulting is provided through in-person workshops, eLearning and workflow tools, diagnostic and assessment offerings, and other sales acceleration modules. Underpinned by the world-renowned, research-based Challenger™ methodology, Challenger’s solutions help enterprises adopt, develop, communicate and implement more effective commercial strategies on a global scale. For more information, visit www.challengerinc.com.
Media Contact:
Andrea Grodnitzky
Chief Marketing Officer
Richardson Sales Performance
215-940-9255
[email protected]
Logo – https://mma.prnewswire.com/media/1178731/Richardson_Sales_Performance_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/richardson-sales-performance-announces-acquisition-of-challenger-uniting-two-industry-leaders-to-redefine-the-future-of-sales-training-302248218.html
Fintech PR
Blockchain Market to Reach $403.36 Billion by 2030, Driven by Rising Demand for Secure and Transparent Transactions in the BFSI Sector and Growing Popularity of Cryptocurrency – Exclusive Report by Meticulous Research®
REDDING, Calif., Sept. 16, 2024 /PRNewswire/ — According to a new market research report titled, ‘Blockchain Market by Type (Public, Private, Hybrid, Consortium), Platform (Ethereum, Hyperledger, Polygon, Solana), Organization Size, Sector (BFSI, Government, Healthcare, Professional Services, Manufacturing), and Geography—Global Forecast to 2030.
The blockchain market is projected to reach $403.36 billion by 2030, at a CAGR of 67.7% from 2023 to 2030.
Download FREE PDF Brochure Of Blockchain Market – https://www.meticulousresearch.com/download-sample-report/cp_id=5526
The growth of this market is mainly driven by the rising demand for secure and transparent transactions in the BFSI sector, the surging need to prevent data tampering in the healthcare sector, and the growing popularity of cryptocurrency. However, the high costs of blockchain implementation restrain the growth of this market.
Furthermore, SMEs’ focus on leveraging blockchain and the increasing adoption of blockchain among retailers are expected to create significant growth opportunities for the players in this market. However, regulatory uncertainties and the lack of interoperability between blockchain ecosystems are major challenges impacting market growth.
Get Insightful Data On Regions, Market Segments, Customer Landscape, And Top Companies (Charts, Tables, Figures And More) – https://www.meticulousresearch.com/request-sample-report/cp_id=5526
Increasing Need to Prevent Data Tampering Driving the Adoption of Blockchain Technology in the Healthcare Sector
The growing popularity of cryptocurrency and the need to prevent data tampering in the healthcare sector are key factors increasing the adoption of blockchain technology. Cryptocurrencies, such as Bitcoin, have gained traction in recent years, showcasing the potential of decentralized digital currencies that rely on blockchain technology for secure and transparent transactions. Data integrity and security are of paramount importance in the healthcare sector. Medical records, clinical trial data, and patient information must be protected from unauthorized access, tampering, or alteration. With blockchain technology, healthcare organizations can securely store and share patient records, ensuring the security and integrity of sensitive information. The distributed nature of blockchain technology eliminates the reliance on a single centralized authority, reducing the risk of data manipulation or tampering. The players in this market are focused on launching new offerings for healthcare applications. For instance, in October 2020, IBM Watson Health (U.S.) launched a blockchain-powered digital health pass. This digital health initiative was aimed at allowing users to share their verified health status without exposing the data used to generate it.
Explore the Key Market Segments Driving Growth (Download Free Sample) – https://www.meticulousresearch.com/download-sample-report/cp_id=5526
Blockchain Market Analysis: Key Findings
- By Type: In 2023, the public segment accounted for the largest share of 66.9% of the blockchain market. However, the private segment is expected to register the highest CAGR of 70.3% during the forecast period 2023–2030.
- By Platform: In 2023, the Ethereum segment accounted for the largest share of 53.8% of the blockchain market. However, the Hyperledger segment is expected to register the highest CAGR of 71.0% during the forecast period 2023–2030.
- By Organization Size: In 2023, the large enterprises segment accounted for the major share of 74.0% of the blockchain market. However, the small & medium-sized enterprises segment is expected to register the higher CAGR of 70.1% during the forecast period 2023–2030.
- By Application: In 2023, the payments segment accounted for the largest share of 25.2% of the blockchain market. Also, the payments segment is expected to register the highest CAGR of 69.3% during the forecast period 2023–2030.
- By Sector: In 2023, the BFSI segment accounted for the largest share of 41.2% of the blockchain market. However, the healthcare & life sciences segment is expected to register the highest CAGR of 80.2% during the forecast period 2023–2030.
Have specific research needs? Request a customized research report – https://www.meticulousresearch.com/request-customization/cp_id=5526
Blockchain Market Analysis by Segment with Projected CAGR (2023–2030)
|
Category |
2023 Largest Share |
% Share (2023) |
Highest CAGR (2023-2030) |
CAGR % (2023-2030) |
|
By Type |
Public Segment |
66.90 % |
Private Segment |
70.30 % |
|
By Platform |
Ethereum Segment |
53.80 % |
Hyperledger Segment |
71.00 % |
|
By Organization Size |
Large Enterprises Segment |
74.00 % |
Small & Medium Enterprises |
70.10 % |
|
By Application |
Payments Segment |
25.20 % |
Payments Segment |
69.30 % |
|
By Sector |
BFSI Segment |
41.20 % |
Healthcare & Life Sciences |
80.20 % |
Geographic Analysis:
Based on geography, the blockchain market is segmented into North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa. In 2023, North America accounted for the largest share of 38.9% of the blockchain market. This market is projected to reach $136. 4 Billion by 2030.
Financial service industries across North America are poised for transformative change, and leading corporations and start-ups are increasingly investing in fintech. The increasing use of technologies within business ecosystems, the growing number of financial firms, millennials’ preference for digital applications and services for task completion, the rising demand for high-speed apps, and the growing need for real-time data transfer capabilities are expected to support the growth of the blockchain market in North America over the forecast period.
Browse In-depth Report Now – https://www.meticulousresearch.com/product/blockchain-market-5526
Furthermore, the presence of several blockchain providers across North America has also contributed to the region’s large market size. For instance, North America is home to some of the most popular blockchain development companies around the globe, including IBM and Amazon Web Services Inc. These companies are actively focusing on the development of innovative blockchain products. Additionally, governments in the region have undertaken several initiatives to support the adoption and raise awareness regarding blockchain technology.
In 2023, the U.S. accounted for the dominant share of 95.4% of the blockchain market in North America. The country’s large market share is mainly attributed to the increasing demand for decentralized financial solutions, the presence of leading blockchain development companies, and the increasing implementation of blockchain technology across retail, government, and BFSI organizations.
Get A Glimpse Inside: Request Sample Pages – https://www.meticulousresearch.com/request-sample-report/cp_id=5526
The high potential for the widespread adoption of blockchain technology across the financial services sector, the increasing development of digital currencies and fast payment methods, and the emergence of cryptocurrencies such as bitcoin are driving the growth of the blockchain market in the U.S. Furthermore, research and investments in blockchain technology are creating notable brands such as Libra (Facebook), JPM coin (JPMorgan) and Gemini coin (Winklevoss brothers), broadening the scope of the blockchain market. Leading blockchain providers are implementing solutions across the U.S. to ensure safe & secure transactions. For instance, in April 2021, BitGo (U.S.) implemented blockchain solutions to enable security for CoinLoan (Estonia) clients across the U.S.
Asia-Pacific: The Fastest-growing Regional Market
Asia-Pacific is projected to register the highest CAGR of 71.5% during the forecast period. In 2023, China accounted for the largest share of the blockchain market in Asia-Pacific. Market growth in APAC is attributed to the surging demand for safe transactions across international borders, the growing number of crypto-related businesses, and rising disposable incomes. Government policies and initiatives incorporating blockchain technology in the public sector are also expected to create growth opportunities for the players in this market.
The Asia-Pacific region is a leading fintech powerhouse due to the presence of hotspots, including Hong Kong, Singapore, Melbourne, and Indonesia. The presence of Chinese fintech hubs across Beijing, Shanghai, and Shenzhen, the increasing number of fintech companies across India, and the growing demand for friction-free, peer-to-peer transactions are driving the growth of the blockchain market in APAC.
Governments in the region have recognized the potential of blockchain technology and have launched initiatives to support its development. For example, China has expressed a strong interest in blockchain and has invested heavily in research and development. Singapore has also created a conducive environment for blockchain start-ups through regulatory frameworks and funding. These government initiatives contribute to market growth in the region.
Need Insights on Regional Data? Check Out Our Detailed Analysis (Download Free Sample) – https://www.meticulousresearch.com/download-sample-report/cp_id=5526
The U.K. Continues to Dominate the Blockchain Market in Europe
In 2023, the U.K. accounted for the largest share of the blockchain market in Europe. Factors driving market growth in the U.K. include the strong presence of leading financial firms, supportive government initiatives, and advances in fintech.
Blockchain has driven innovation across industries in the U.K. The emergence of distributed ledger technologies, such as blockchain, is influencing industries in the U.K., owing to the rapid development and proliferation of blockchain applications across the country. For instance, in March 2021, the London Stock Exchange partnered with IBM Corporation (U.S.) to develop Turquoise, a blockchain-based platform for issuing digital securities. The platform streamlines post-trade processes, enhances transparency, and attracts new investors by leveraging the benefits of blockchain technology.
Furthermore, Walmart (U.S.) implemented a blockchain solution for tracking and tracing food products in its U.K. stores. This solution helps ensure food safety, improves efficiency, and builds consumer trust. Blockchain technology can also revolutionize healthcare systems by improving data management, patient privacy, and interoperability. In the U.K., the National Health Service (NHS) implemented blockchain in the MediLedger Project led by the NHS National Innovation Center (NIC). This project aims to leverage blockchain to share medical research data securely and efficiently. These factors contribute to market growth in the country.
Need Insights on Regional Data? Check Out Our Detailed Analysis (Download Free Sample) – https://www.meticulousresearch.com/download-sample-report/cp_id=5526
Blockchain Market: Competition Analysis
This report offers a competitive analysis based on an extensive assessment of the leading players’ product portfolios, geographic presence, and key growth strategies adopted over the past 3–4 years. Major companies in the blockchain market have implemented various strategies to expand their product offerings and global footprints and augment their market shares. The key strategies followed by leading companies in the blockchain market include product launches, expansions, mergers & acquisitions, agreements, collaborations, and partnerships. The key players operating in the blockchain market include IBM Corporation (U.S.), Microsoft Corporation (U.S.), Oracle Corporation (U.S.), Amazon Web Services, Inc. (U.S.), Infosys Limited (India), Accenture plc (Ireland), Wipro Limited (India), Blockchain.com (U.K.), Circle Internet Financial Limited (U.S.), Ripple (U.S.), Tata Consultancy Services Limited (India), Intel Corporation (U.S.), Chainalysis Inc. (U.S.), Coinbase (U.S.), and BitGo (U.S.).
Learn About the Top Companies Influencing Market Dynamics (Download Free Sample) – https://www.meticulousresearch.com/request-sample-report/cp_id=5526
Blockchain Industry Overview: Latest Developments from Key Industry Players
- In January 2023, Amazon Web Services (U.S.) launched Avalanche to help bring blockchain technology to enterprises and governments. Avalanche is the first blockchain integrated with Amazon’s cloud-computing platform.
- In January 2023, Ava Labs (Brooklyn) partnered with Amazon Web Services (U.S.) to allow individuals and institutions to launch subnets that can operate as self-sufficient blockchain systems.
- In November 2022, Accenture plc collaborated with NTT DOCOMO (Japan) to accelerate the adoption and application of Web3 for addressing social issues.
- In October 2022, Oracle Corporation launched its Oracle Database 23c Beta, the new version of the world’s most widely used converged database that supports all data types, workloads, and development styles.
- In August 2022, Infosys Limited partnered with VMware (U.S.) to launch a blockchain-based vital records management solution.
- In May 2022, Keep Sea Blue (Athens), an international and independent association, collaborated with Oracle Corporation (U.S.) to use Oracle’s blockchain technology to fight plastic pollution and keep the Mediterranean clean.
- In November 2021, Infosys Finacle (India), a wholly-owned subsidiary of Infosys, collaborated with IBM Corporation (U.S.) to make the Finacle Digital Banking Solution available on Red Hat OpenShift and IBM Cloud with blockchain technology for Financial Services.
- In August 2021, IBM Corporation (U.S.) collaborated with NPTEL to offer a 12-week online course on blockchain architecture, design, and use cases.
- In January 2021, IBM Corporation (U.S.) partnered with Thai Reinsurance Public Company Limited (Thailand) to launch ASEAN’s first reinsurance smart contract platform using its blockchain and hybrid cloud technology.
- In January 2021, Microsoft Corporation (U.S.) collaborated with Invest India to empower tech start-ups. The start-ups shortlisted by Microsoft included Whrrl Fintech Solutions, a company that empowers farmers, traders, and producer companies on a blockchain platform to raise working capital to tide over lengthy crop cycles.
IMMEDIATE DELIVERY AVAILABLE | BUY THIS RESEARCH REPORT (Insights, Charts, Tables, Figures and More)- https://www.meticulousresearch.com/Checkout/43525727
Scope of the Report:
Blockchain Market Assessment—by Type
- Public
- Private
- Hybrid
- Consortium
Blockchain Market Assessment—by Platform
- Ethereum
- Hyperledger
- R3 Corda
- Polygon
- Solana
- BSC
- Terra
- Other Platforms
Blockchain Market Assessment—by Organization Size
- Large Enterprises
- Small & Medium-sized Enterprises
Blockchain Market Assessment—by Application
- Digital Currency
- Asset Protection & Transfer
- Identity Protection
- Payments
- Data Reconciliation & Sharing
- Track & Trace
- Certification
- Other Applications
Blockchain Market Assessment—by Sector
- BFSI
- Government
- Healthcare & Life Sciences
- Retail & E-commerce
- Energy & Utilities
- Professional Services
- Media & Entertainment
- Manufacturing
- Other Sectors
Blockchain Market Assessment—by Geography
- North America
- U.S.
- Canada
- Asia-Pacific (APAC)
- China
- Japan
- India
- South Korea
- Australia & New Zealand
- Singapore
- Rest of Asia-Pacific (RoAPAC)
- Europe
- Germany
- U.K.
- France
- Italy
- Spain
- Sweden
- Rest of Europe (RoE)
- Latin America
- Brazil
- Mexico
- Rest of Latin America (RoLATAM)
- Middle East & Africa
- UAE
- Israel
- Rest of Middle East & Africa
Browse More Related Reports:
Blockchain in Manufacturing Market by Size, Share, Forecasts, & Trends Analysis – https://www.meticulousresearch.com/product/blockchain-in-manufacturing-market-5016
Blockchain in retail market to hit $25.8 Billion by 2029, growing at 68.3% CAGR. Explore its impact on transaction management, supply chain. – https://www.meticulousresearch.com/product/blockchain-in-retail-market-5376
Blockchain Market to hit $403.36 Billion by 2030, growing at a 67.7% CAGR from 2023. Explore growth trends and future opportunities in this booming industry. – https://www.meticulousresearch.com/product/blockchain-market-5526
Blockchain gaming market is projected to reach $165.4 billion by 2030, at a CAGR of 51.7% during the forecast period 2024–2030 – https://www.meticulousresearch.com/product/blockchain-gaming-market-5540
Blockchain Market Research Report Summary
|
Report Metrics |
Details |
|
Base year considered |
2022 |
|
Forecast period |
2023-2030 |
|
CAGR |
CAGR 67.70% |
|
Market Size |
$403.36 billion |
|
Segments Covered |
By Type (Public, Private, Hybrid, Consortium), Platform (Ethereum, Hyperledger, Polygon, Solana), Organization, Sector (BFSI, Government, Healthcare, Professional Services, Manufacturing), and Geography |
|
Geographies covered |
North America, Europe, Asia Pacific, Middle East & Africa, Latin America |
|
Companies covered |
International Business Machines Corporation (U.S.), Microsoft Corporation (U.S.), Oracle Corporation (U.S.), Amazon Web Services, Inc. (U.S.), Infosys Limited (India), Accenture plc (Ireland), Wipro Limited (India), Blockchain.com (U.K.), Circle Internet Financial Limited (U.S.), Ripple (U.S.), Tata Consultancy Services Limited (India), Intel Corporation (U.S.), Chainalysis Inc. (U.S.), Coinbase (U.S.), and BitGo (U.S.). |
Click here to: Get a Free Sample Copy of this report
Hot Industry Reports: Emerging Trends and Market Forecasts
Chromatography Syringes Market by Size, Share, Forecasts, & Trends Analysis – https://www.meticulousresearch.com/product/chromatography-syringes-market-3242
VNA and PACS Market by Size, Share, Forecasts, & Trends Analysis – https://www.meticulousresearch.com/product/vna-and-pacs-market-4440
Dental Materials Market by Size, Share, Forecast, & Trends Analysis – https://www.meticulousresearch.com/product/dental-materials-market-3182
Pharmaceutical Storage And Material Handling Equipment Market by Size, Share, Forecasts, & Trends Analysis – https://www.meticulousresearch.com/product/pharmaceutical-storage-and-material-handling-equipment-market-4364
Tooth Replacement Market by Size, Share, Forecast, & Trends Analysis – https://www.meticulousresearch.com/product/tooth-replacement-market-3155
Electronic Lab Notebook Market by Size, Share, Forecasts, & Trends Analysis – https://www.meticulousresearch.com/product/electronic-lab-notebook-eln-market-4341
Hydroponics Market by Size, Share, Forecasts, & Trends Analysis – https://www.meticulousresearch.com/product/hydroponics-market-5434
Laboratory Informatics Market by Size, Share, Forecasts, & Trends Analysis – https://www.meticulousresearch.com/product/laboratory-informatics-market-3945
Sorbitol Market by Size, Share, Forecasts, & Trends Analysis – https://www.meticulousresearch.com/product/sorbitol-market-3019
Mice Model Market by Size, Share, Forecast, & Trends 2023 – 2030 – https://www.meticulousresearch.com/product/mice-model-market-4151
High Throughput Screening Market Size, Share, Forecast, & Trends 2031 – https://www.meticulousresearch.com/product/high-throughput-screening-market-3206
Veterinary Immunodiagnostics Market by Size, Share, Forecasts, & Trends Analysis – https://www.meticulousresearch.com/product/veterinary-immunodiagnostics-market-2897
Life Science Equipment Market by Size, Share, Forecast, & Trends Analysis – https://www.meticulousresearch.com/product/life-science-equipment-market-3937
Cell Culture Market Size, Share, Growth, & Trends 2029 – https://www.meticulousresearch.com/product/cell-culture-market-4788
Bakery Processing Equipment Market Size, Share, Report 2030 – https://www.meticulousresearch.com/product/bakery-processing-equipment-market-4854
Inspection Machines Market Size, Share, Forecasts, & Trends Analysis – https://www.meticulousresearch.com/product/inspection-machines-market-2571
Modified Starch Market Size, Share, Forecast, & Trends Analysis – https://www.meticulousresearch.com/product/modified-starch-market-2718
Industrial Margarine Market Size, Share, Forecast, & Trends Analysis – https://www.meticulousresearch.com/product/industrial-margarine-market-3837
Plasmapheresis Market by Size, Share, Forecasts, & Trends Analysis – https://www.meticulousresearch.com/product/plasmapheresis-market-3092
Biopharmaceutical Processing Equipment and Consumables Market Size – https://www.meticulousresearch.com/product/biopharmaceutical-processing-equipment-and-consumables-market-4200
Lipid Nutrition Market by Size, Share, Forecast, & Trends Analysis – https://www.meticulousresearch.com/product/lipid-nutrition-market-3045
Telehealth Market: Size, Trends & Forecast Analysis to 2029 – https://www.meticulousresearch.com/product/telehealth-market-4174
IVD Quality Control Market Size, Share, Forecast, & Trends – https://www.meticulousresearch.com/product/ivd-quality-control-market-3447
Population Health Management (PHM) Solutions Market by Size, Share, Forecasts, & Trends Analysis – https://www.meticulousresearch.com/product/population-health-management-solutions-phm-market-3897
North America Telehealth Market by Size, Share, Forecasts, & Trends Analysis – https://www.meticulousresearch.com/product/north-america-telehealth-market-4832
South East Asia Food Processing Equipment Market by Size, Share, Forecasts, & Trends Analysis – https://www.meticulousresearch.com/product/south-east-asia-food-processing-equipment-market-4194
Chromatography Data Systems Market by Size, Share, Forecasts, & Trends Analysis – https://www.meticulousresearch.com/product/chromatography-data-systems-market-2933
Healthcare Artificial Intelligence Market Growth and Trends – https://www.meticulousresearch.com/product/healthcare-artificial-intelligence-market-4937
Latin America Home Healthcare Market by Size, Share, Forecasts, & Trends Analysis – https://www.meticulousresearch.com/product/latin-america-home-healthcare-market-1287
Speech and Voice Recognition Market Size, Share, Forecast, & Trends Analysis – https://www.meticulousresearch.com/product/speech-and-voice-recognition-market-5038
Contact:
Mr. Khushal Bombe
Meticulous Market Research Inc.
1267 Willis St, Ste 200 Redding,
California, 96001, U.S.
USA: +1-646-781-8004
Europe: +44-203-868-8738
APAC: +91 744-7780008
Email- [email protected]
Visit Our Website: https://www.meticulousresearch.com/
Connect with us on LinkedIn- https://www.linkedin.com/company/meticulous-research
Meticulousblog.org | Top Market Research Reports Blog – https://meticulousblog.org/
Content Source: https://www.meticulousresearch.com/pressrelease/757/blockchain-market
Photo: https://mma.prnewswire.com/media/2506362/Blockchain_Market_Size.jpg
Logo: https://mma.prnewswire.com/media/1757980/Meticulous_Research_Logo_1.jpg
View original content:
Epitomee’s Ingestible Capsule, Offers a Safe and Effective Prescription Solution for Adults with BMI of 25-40 looking for Alternative Drug Free Solutions for Their Weight Management Needs alongside diet and exercise.
CAESAREA, Israel, Sept. 16, 2024 /PRNewswire/ — Epitomee Medical Ltd. (TASE: EPIT), announced that the United States Food and Drug Administration (FDA) has officially cleared the Epitomee® Capsule, a cutting-edge ingestible medical device designed to support weight management in adults with a Body Mass Index (BMI) of 25–40 kg/m² alongside diet and exercise. This novel, drug-free treatment provides a new option for millions of health-conscious individuals in the U.S.
The Epitomee® Capsule represents an innovative prescription option in weight management solutions, offering a drug-free alternative that differs from injectable treatments. With FDA clearance extending to adults with a BMI starting at 25, Epitomee® Capsule is accessible to a broader range of patients looking for tolerable and easy to use weight management solutions. The Epitomee® device is encased in a standard size, self-administered ingestible capsule. Once the Epitomee® Capsule is swallowed, and reaches the stomach it absorbs water in the stomach and creates a three-dimensional matrix designed to occupy volume in the stomach creating a sensation of fullness, enabling weight loss. The Epitomee® Capsule mechanism of action is purely mechanical and does not involve any chemical activity. The capsule works directly in the gastrointestinal (GI) tract.
Epitomee® Capsule was cleared by the U.S. FDA following the RESET study: A prospective, randomized, double-blind, placebo-controlled, multi-canter trial. The study enrolled 279 overweight and obese adults with and without prediabetes. All 9 sites enrolled in the study were in the US, located across 9 different states. Eligible subjects were randomized to test or placebo arms. Subjects were to take one capsule of the investigational device or placebo twice daily , alongside diet and exercise, for a period of 24 weeks. The study demonstrated that both co-primary endpoints were successfully met. The RESET study demonstrated significantly better weight loss among the device group compared to the control group (P<0.0001). The co-primary endpoint of treatment responders was also achieved: the rate of Epitomee treatment group subjects whose total body weight was reduced by at least 5% at 24-weeks post randomization was 55.5% (CI; 46.1-64.6), significantly exceeding the threshold of >35% (P<0.0001).
The study demonstrated a favourable safety profile of Epitomee® treatment throughout the study duration. Epitomee® treatment was well tolerated, with fewer patient dropouts in Epitomee® group than the control group. There were no serious adverse device effects (SADEs) in the study. In addition, subjects treated with Epitomee® showed better improvement in quality of life in several items of the IWQOL-Lite-CT questionnaire.
The company also performed an additional study in 3 out of the 9 sites that participated in the RESET study, the ELECT study. In this study subjects from both the device group and the placebo group kept on taking the Epitomee® capsule for an additional 24 week period. The study demonstrated a favourable safety profile of Epitomee® treatment throughout the 48 weeks of the study duration for subjects in the device group.
Shimon Eckhouse PhD co-founder and chairman of the board, commented on the approval: “The FDA clearance of the Epitomee® Capsule marks a significant milestone in the field of weight management. Its innovative approach offers a safe and effective option for patients. The ability to manage weight through a simple, drug free capsule opens up new possibilities for those seeking to improve their health and quality of life.”
Dan Hashimshony PhD, CEO of Epitomee Medical Ltd., commented: “We are proud to have received FDA clearance for our Epitomee® weight management Oral, Drug-Free solution. This achievement is the result of the innovative approach we have taken to tackle the global obesity epidemic. Our capsule offers a safe, effective, and drug-free solution to the many millions of individuals struggling with weight management. As we move forward, we are eager to bring this groundbreaking product to the U.S. market and seek strategic partnerships to fully realize its commercial potential.”
About Epitomee Medical Ltd.
Epitomee Medical Ltd, a public company (TASE: EPIT), co-founded in 2005 by Shimon Eckhouse, PhD and led by CEO Dan Hashimshony PhD. Shimon co-founded Syneron Medical Ltd. (Nasdaq: ELOS), Lumenis (formally ESC Medical) and co-founded Ventor Medical Technologies, which was acquired by Medtronic. Dan was the founding CEO of Dune Medical Devices, a surgical oncology company (acquired by Dilon Technologies). Prior to that, Dan was with X-Technologies (acquired by Guidant in 2003) and Sela Semiconductor (acquired by Camtek).
The company is a pioneering health solutions company, committed to advancing innovative therapies. With focus on safety, efficacy, and improving quality of life, Epitomee Medical strives to be at the forefront of transformative healthcare solutions.
The company is advancing two major fields: weight management and biologic drug delivery. In addition to its flagship weight management solution, Epitomee Medical is developing a cutting-edge platform focused on the oral delivery of biologics. This innovative platform is designed to transport drugs to the absorption site with enhanced bioavailability.
For more information about Epitomee Medical Ltd., please visit Epitomee Medical (https://epitomeemedical.com/)
For partnership inquiries and more information about the Weight-management capsule – contact:
Mr. Alon Heth
VP Sales and Marketing
[email protected]
Photo – https://mma.prnewswire.com/media/2506355/Epitomee_Medical.jpg
Logo – https://mma.prnewswire.com/media/2506356/Epitomee_Medical_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/epitomee-medical-announces-fda-clearance-of-its-capsule-weight-management-device-302249169.html
-
Fintech PR6 days agoInternational leaders discuss proposals for global food security and sustainability at FIAP in Cuiabá (MT)
-
Fintech PR6 days agoProdigy Finance Launches $30 Million Blended Finance Programme to Enable the Next Generation of African Leaders
-
Fintech PR5 days agoGlobal Health Exhibition Announces Opportunity for Healthcare Startups to secure over 100,000 SAR in Vision NextGen Competition Designed to Fast-Track Health Innovations
-
Fintech7 days agoGaia-X Introduces the Compliance Document to Enable and Increase Trust, Security, and European Sovereignty in Digital Ecosystems
-
Fintech PR5 days agoOffice of family of Yerzhan Tatishev fight for justice: Convicted assassin could be released early in Kazakhstan
-
Fintech PR6 days agoNaqdi Secures SCA License, Strengthening Its Commitment to Transparency and Innovation in the UAE
-
Fintech PR5 days agoOnix Positioned as the Leader in the 2024 SPARK Matrix for Cloud Cost Management & Optimization by QKS Group
-
Fintech PR5 days agoQNB Share Buyback